Medicare Is Paying for Hemp CBD Products That the FDA Hasn’t Approved. That’s the Problem.

On April 1, 2026, a quiet but significant thing happened in federal health policy: the Centers for Medicare & Medicaid Services launched a program that lets Medicare-connected care organizations give patients up to $500 per year in hemp-derived CBD products.

There’s just one problem. The FDA hasn’t approved any of those products as medicines.

That contradiction is now the center of a federal lawsuit — and it’s a clean example of what happens when federal agencies start moving in opposite directions on the same substance.

What the CMS Program Actually Does

The program is called the Substance Access Beneficiary Engagement Incentive (BEI). It’s structured as a “pilot,” which gives CMS room to maneuver without a formal rulemaking process. Under the BEI, Accountable Care Organizations (ACOs) — the Medicare-funded groups that coordinate care for beneficiaries — can provide up to $500 per patient per year in hemp-derived products as a kind of wellness supplement.

CMS frames this carefully: it’s not “reimbursement,” the agency says, because the products aren’t being prescribed as drugs. They’re being offered as engagement incentives — a nudge toward healthcare participation. The money flows from ACO budgets that are ultimately financed by Medicare.

The distinction matters legally, but it’s one that a patient receiving a bottle of hemp CBD capsules through their Medicare-connected doctor probably isn’t going to notice.

Why the FDA Has a Problem With This

The FDA has spent years maintaining a bright line: if a substance is being used therapeutically — to treat a condition, improve health outcomes, or manage symptoms — it needs to go through a drug approval process first. That process exists to verify safety, efficacy, and manufacturing quality.

Hemp-derived CBD products sold at retail have not gone through that process. The only FDA-approved CBD drug is Epidiolex, a pharmaceutical-grade formulation approved for specific forms of epilepsy. Everything else — the tinctures, gummies, and softgels — remains in a legal grey zone where the FDA tolerates their sale as supplements but has never authorized them as medicines.

What CMS just did, critics argue, is effectively push those retail-grade products through a backdoor into the federal healthcare system. No clinical trials. No drug approval. Just an administrative pilot program and $500 per patient.

The Lawsuit

On March 31, 2026 — one day before the BEI went live — Smart Approaches to Marijuana (SAM) filed suit in the U.S. District Court for the District of Columbia. The case, SAM et al. v. Kennedy et al. (Case 1:26-cv-01081), names CMS Administrator Dr. Mehmet Oz as a defendant.

The complaint argues two things: first, that CMS violated the Administrative Procedure Act by launching the program without proper notice-and-comment rulemaking; second, that the program violates the Federal Food, Drug, and Cosmetic Act by effectively reimbursing products that haven’t been proven safe and effective through FDA review.

MMJ International Holdings, a pharmaceutical company that has spent nearly a decade pursuing FDA-pathway approval for cannabinoid-based medicines for Huntington’s Disease and Multiple Sclerosis, subsequently moved to join the lawsuit as an intervenor. Their argument adds a market-distortion angle: a company that invested millions following the FDA’s rules is now competing against retail hemp products that get federal funding without any of those requirements.

“Reimbursement cannot replace evidence,” said Duane Boise, MMJ’s CEO. “Coverage is not approval.”

The Congressional Wild Card

There’s a third federal actor here, and it may be the one that matters most in the long run.

Congress is expected to tighten the definition of ingestible hemp cannabinoids later this year under the 2026 Agriculture Appropriations Act. If that legislation passes, it could recriminalize many of the exact products that CMS is currently incentivizing — creating a scenario where Medicare dollars are flowing toward hemp CBD products that Congress simultaneously decides should be federally restricted.

That’s not a hypothetical grey zone. That’s a collision of federal agencies that hasn’t been resolved.

What This Means in Practice

For most hemp consumers, the CMS pilot doesn’t change much directly — it applies to Medicare beneficiaries getting products through ACO-affiliated care programs, not to retail customers buying from a dispensary or online.

But the broader implications are real:

For retailers and manufacturers: If CMS’s framework survives legal challenge, it creates a precedent that hemp-derived products can receive something functionally equivalent to federal healthcare funding without FDA approval. That’s either a major expansion of the market or a regulatory time bomb, depending on what Congress does next.

For compliance officers: The program underscores a growing problem: multiple federal agencies now have active, contradictory positions on hemp-derived ingestibles. FDA says no drug claims. CMS says here’s $500 for your patients. Congress is about to say something else entirely. Building a compliance strategy that accounts for all three is genuinely difficult right now.

For consumers: Anyone receiving hemp products through a Medicare-connected program should understand that “covered by Medicare” does not mean “FDA-approved.” Those are different standards. The products you’d receive under the BEI are the same retail-grade supplements sold on Amazon and in gas stations — not pharmaceutical-grade drugs with verified dosing and safety profiles.

The Deeper Problem

What makes this story representative of The Grey Zone is that no one here is obviously wrong on their own terms.

CMS is trying to expand access to products that have a large consumer base and some preliminary evidence of benefit. FDA is protecting a drug-approval system that exists for real reasons. Congress is responding to constituent pressure and industry lobbying. MMJ Holdings is making a legitimate argument about regulatory fairness.

The problem is that all of these positions are being executed simultaneously, by agencies that answer to the same federal government, without coordination. The result is a program that’s been live for nine days and is already the subject of a federal lawsuit, with potential legislation that could undermine it before the year is out.

That’s not a regulatory grey zone. That’s a regulatory train wreck in slow motion — and hemp CBD consumers, retailers, and manufacturers are standing on the tracks.

Morgan Ellis covers hemp-derived THC regulation, Farm Bill grey zones, and FDA enforcement for The Grey Zone at CannabisInquirer.com. See also: current legal status of delta-8 THC in the United States.